2024 targets achieved; markets appreciated shareholder rewards

30/01/25 -"Even though Q4 results were somewhat behind the consensus, Sanofi slightly exceeded its 2024 guidance. The 2025 outlook was encouraging. Moreover, the investors welcomed the management’s ..."

Executive summary
Conflict of interest

Pages

Language

English

Published on

30/01/25

Download

You may also be interested by these reports :

19/06/26

PHARMA

Evaluating Pharma’s Defences

17/06/26

Siegfried

Our target price is reduced to CHF94 (from CHF97) on the back of a lower sales base. We have also adjusted forward years’ growth, slightly increasing ...

15/06/26

PolyPeptide

The target price is upgraded on the back of higher margins in 2026. The EBITDA margin is lifted from 15.4% to 17.9% for the full year (guidance is ...

09/06/26

Lonza Group

Our estimates for 2026-2027 have been revised downward following the reclassification of Capsules & Health Ingredients (CHI) as discontinued ...

EXECUTIVE SUMMARY

Updates

Pension Risks

Target & Opinion

Governance & Management

Business & Trends

Graphics : Momentum

Money Making

Graphics : MACD & Volumes

Debt

Graphics : Sensitivities

Valuation

Sector: Performance

DCF

Sector: Key data

NAV/SOTP

Sector: Ratios & Valorisation

Worth knowing

Sector: Peers

Financials

Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking

Trading in corporate shares

Analyst ownership

Advising of corporate (strategy, marketing, debt, etc)

Research paid for by corporate

Provision of corporate access paid for by corporate

Link between and a banking entity

Brokerage activity at AlphaValue